請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/73236完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 周玉山(Yuh-Shan Jou) | |
| dc.contributor.author | Chen-Hao Hsiao | en |
| dc.contributor.author | 蕭丞皓 | zh_TW |
| dc.date.accessioned | 2021-06-17T07:23:56Z | - |
| dc.date.available | 2022-07-15 | |
| dc.date.copyright | 2019-07-15 | |
| dc.date.issued | 2019 | |
| dc.date.submitted | 2019-07-01 | |
| dc.identifier.citation | 1. Light RW. Parapneumonic effusions and empyema. Proc Am Thorac Soc 2006;3:75-80.
2. Brook I, Frazier EH. Aerobic and anaerobic microbiology of empyema. A retrospective review in two military hospitals. Chest 1993;103:1502-1507. 3. Chapman SJ, Davies RJ. Recent advances in parapneumonic effusions and empyema. Curr Opin Pulm Med 2004;10:229-304. 4. Schweigert M, Solymosi N, Dubecz A, Fernandez MJ, Stadlhuber RJ, Ofner D, Stein HJ. Surgery for parapneumonic pleural empyema – What influence does the rising prevalence of multimorbidity and advanced age has on the current outcome? Surgeon 2016;14:69-75. 5. Christopoulou-Aletra H, Papavramidou N. “Empyemas” of the thoracic cavity in the Hippocratic Corpus. Ann Thorac Surg 2008;85:1132-1134. 6. Watkins E, Jr., Fielder CR. Management of nontuberculous empyema. Surg Clin North Am 1961;41:681-693. 7. Waller DA, Rengarajan A. Thoracoscopic decortication: a role for video-assisted surgery in chronic postpneumonic pleural empyema. Ann Thorac Surg 2001;71:1813-1816. 8. Drain AJ, Ferguson JI, Sayeed R, Wilkinson S, Ritchie A. Definite management of advanced empyema by two-window video-assisted surgery. Asian Cardiovasc Thorac Ann 2007;15:238-239. 9. Wozniak CJ, Paull DE, Moezzi JE, Scott RP, Anstadt MP, York VV, Lottle AG. Choice of first intervention is related to outcomes in the management of empyema. Ann Thorac Surg 2009;87:1525-1530. 10. Bagheri R, Tavassoli A, Haghi SZ, Attaran D, Sadrizadeh A, Asnaashari A, Basiri R, Salehi M, Moghadam KA, Tabari A, Sheibani S. The role of thoracoscopic debridement in the treatment of parapneumonic empyema. Asian Cardiovasc Thorac Ann 2013;21:443-446. 11. Shin JA, Chang YS, Kim TH, Haam SJ, Ahn CM, Byun MK. Surgical decortication as the first-line treatment for pleural empyema. J Thorac Cardiovasc Surg 2013;145:933-939. 12. Chung JH, Lee SH, Kim KT, Jung JS, Son HS, Sun K. Optimal timing of thoracoscopic drainage and decortication for empyema. Ann Thorac Surg 2014;97:224-229. 13. L Colice G, Idell S. Counterpoint: should fibrinolytics be routinely administered intrapleurally for management of a complicated parapneumonic effusion? No. Chest 2014;145:17-20. 14. Bar I, Stav D, Fink G, Peer A, Lazarovitch T, Papiashvilli M. Thoracic empyema in high-risk patients: conservative management or srgery? Asian Cardiovasc Thorac Ann 2010;18:337-343. 15. Herrera-Kiengelher L, Baez-Saldana R, Salas-Hernandez J, Avalos-Bracho A, Perez-Padilla R, Torre-Bouscoulet L. Frequency of adverse events and mortality in patients with pleural empyema in a public referral hospital in Mexico City. Int J Tuberc Lung Dis 2010;14:1187-1192. 16. Meta-analysis Global Group in Chronic Heart Failure. The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J 2012;33:1750-1757. 17. Corcoran JP, Rahman NM. Point: should fibrinolytics be routinely administered intrapleurally for management of a complicated parapneumonic effusion? Yes. Chest 2014;145:14-17. 18. Chen JS, Cheng YJ, Hung MH, Tseng YD, Chen KC, Lee YC. Nonintubated thoracoscopic lobectomy for lung cancer. Ann Surg 2011;254:1038-1043. 19. Katlic MR, Facktor MA. Video-assisted thoracic surgery utilizing local anesthesia and sedation: 384 consecutive cases. Ann Thorac Surg 2010;90:240-245. 20. Tacconi F, Pompeo E, Fabbi E, Mineo TC. Awake video-assisted pleural decortication for empyema thoracis. Eur J Cardiothorac Surg 2010;37:594-601. 21. Pompeo E, Sorge R, Akopov A, Congregado M, Grodzki T; ESTS Non-intubated Thoracic Surgery Working Group. Non-intubated thoracic surgery-A survey from the European Society of Thoracic Surgeons. Ann Transl Med 2015;3:37. 22. Chen JS, Cheng YJ, Hung MH, Tseng YD, Chen KC, Lee YC. Nonintubated thoracoscopic lobectomy for lung cancer. Ann Surg 2011;254:1038-1043. 23. Mineo TC. Epidural anesthesia in awake thoracic surgery. Eur J Cardiothorac Surg 2007;32:13-19. 24. Migliore M, Giuliano R, Aziz T, Saad R, Sgalambro F. Four-step local anesthesia and sedation for thoracoscopic diagnosis and management of pleural disease. Chest 2002;121:2032-2035. 25. Schweigert M, Solymosi N, Dubecz A, Beron M, Thumfart L, Oefner-Velano D, Stein HJ. Surgical management of pleural empyema in the very elderly. Ann R Coll Surg Engl 2012;94:331-335. 26. Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-483. 27. Ware JE, Jr., Kosinski M, Bayliss MS, McHorney CA, Rogers WH, Raczek A. Comparsion of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Med Care 1995;33:AS264-279. 28. Hsiao CH, Chen KC, Chen JS. Modified single-port non-intubated video-assisted thoracoscopic decortication in high-risk parapneumonic empyema patients. Surg Endosc 2017;31:1719-1727. 29. McCullers JA. Insights into the interaction between influenza virus and pneumococcus. Clin Microbiol Rev 2006;19:571-582. 30. Whitney CG. Changing epidemiology of pneumococcal disease in the era of conjugate vaccines. Curr Epidemiol Rep 2016;3:125-135. 31. Zysk G, Bongaerts RJ, ten Thoren E, Bethe G, Hakenbeck R, Heinz HP. Detection of 23 immunogenic pneumococcal proteins using convalescent-phase serum. Infect Immun 2000;68:3740-3743. 32. de Stoppelaar SF, Bootsma HJ, Zomer A, Roelofs JJ, Hermans PW, van t Veer C, van der Poll T. Streptococcus pneumoniae serine protease HtrA, but not SFP or PrtA, is a major virulence factor in pneumonia. PLoS One 2013;8:e80062. 33. Orihuela CJ, Radin JN, Sublett JE, Gao G, Kaushal D, Tuomanen El. Microarray analysis of pneumococcal gene expression during invasive disease. Infect Immun 2004;72:5582-5596. 34. Laan M, Cui ZH, Hoshino H, Lotvall J, Sjostrand M, Gruenert DC, Skoogh BE, Linden A. Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways. J Immunol 1999;162:2347-2352. 35. Kumar P, Chen K, Kolls JK. Th17 cell based vaccines in mucosal immunity. Curr Opin Immunol 2013;25:373-380. 36. Lu YJ, Gross J, Boqaert D, Finn A, Bagrade L, Zhang Q, Kolls JK, Srivastava A, Lundgren A, Forte S, Thompson CM, Harney KF, Anderson PW, Lipsitch M, Malley R. Interleukin-17A mediates acquired immunity to pneumococcal colonization. PLoS Pathog 2008;4:e1000159. 37. Spicer EJ, Goldenthal El, Ikeda T. A toxicological assessment of curdlan. Food Chem Toxicol 1999;37:455-479. 38. Higashi T, Hashimoto K, Takagi R, Mizuno Y, Okazaki Y, Tanaka Y, Matsushita S. Curdlan induces DC-mediated Th17 polarization via Jagged1 activation in human dendritic cells. Allergol Int 2010;59:161-166. 39. LeibundGut-Landmann S, Gross O, Robinson MJ, Osorio F, Slack EC, Tsoni SV, Schweighoffer E, Tybulewicz V, Brown GD, Ruland J, Reis e Sousa C. Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nat Immunol 2007;8:630-638. 40. Hsu CF, Hsiao CH, Tseng SF, Chen JR, Liao YJ, Chen SJ, Lin CS, Sytwu HK, Chuang YP. PrtA immunization fails to protect against pulmonary and invasive infection by Streptococcus pneumoniae. Respir Res 2018;19:187. 41. Mao Q, Jiang F, Yin R, Wang J, Xia W, Dong G, Ma W, Yang Y, Xu L, Hu J. Interplay between the lung microbiome and lung cancer. Cancer Lett 2018;415:40-48. 42. Jin C, Lagoudas GK, Zhao C, Bullman S, Bhutkar A, Hu B, Ameh S, Sandel D, Liang XS, Mazzilli S, Whary MT, Meyerson M, Germain R, Blainey PC, Fox JG, Jacks T. Commensal microbiota promote lung cancer development via T cells. Cell 2019 Jan 25. pil: S0092-8674(18)31654-4. 43. Bystrom J, Taher TE, Muhyaddin MS, Clanchy FI, Mangat P, Jawad AS, Williams RO, Mageed RA. Harnessing the Therapeutic Potential of Th17 Cells. Mediators Inflamm 2015;2015:205156. 44. Ma QY, Huang DY, Zhang HJ, Wang S, Chen XF. Upregulation of bacterial-specific Th1 and Th17 responses that are enriched in CXCR5+CD4+ T cells in non-small cell lung cancer. Int Immunopharmacol 2017;52:305-309. 45. Peters BA, Hayes RB, Goparaju C, Reid C, Pass HI, Ahn J. The microbiome in lung cancer tissue and recurrence-free survival. Cancer Epidemiol Biomarkers Prev 2019 Feb 7. pil: cebp.0966.2018. 46. Liu Y, O’Brien JL, Ajami NJ, Scheurer ME, Amirian ES, Armstrong G, Tsavachidis S, Thrift AP, Jiao L, Wong MC, Smith DP, Spitz MR, Bondy ML, Petrosino JF, Kheradmand F. Lung tissue microbial profile in lung cancer is distinct from emphysema. Am J Cancer Res 2018;8:1775-1787. 47. American Cancer Society. Cancer Facts and Figures 2007. Atlanta, GA: American Cancer Society, 2007. 48. World Health Organization. WHO histological classification of tumours of the lung. In: Travis WB, Brambilla A, Muller-Hermelinck HK, Harris CC. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press 2004:10. 49. Haiman CA, Stram DO, Wilkens LR, Pike MC, Kolonel LN, Henderson BE, Le Marchand L. Ethnic and racial differences in the smoking-related risk of lung cancer. N Engl J Med 2006;354:333-342. 50. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011;12:175-180. 51. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V, Sobin L; International Association for the Study of Lung Cancer International Staging Committee.; Participating Institutions.. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007 Aug;2(8):706-14. Erratum in: J Thorac Oncol 2007;2:985. 52. Rodenhuis S, van de Wetering ML, Mooi WJ, Evers SG, van Zandwijk N, Bos JL. Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med 1987;317:929-935. 53. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139. 54. Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 2003;8:303-306. 55. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-181. 56. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957. 57. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T; North-East Japan Study Group.. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-2388. 58. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M; West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-128. 59. Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, Duffield EL, Rukazenkov Y, Speake G, Jiang H, Armour AA, To KF, Yang JC, Mok TS. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011;29:2866-2874. 60. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-742. 61. Skoulidis F, Papadimitrakopoulou VA. Targeting the Gatekeeper: Osimertinib in EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer. Clin Cancer Res 2016 Nov 7. doi: 10.1158/1078-0432.CCR-15-2815. 62. Lee CK, Brown C, Gralla RJ, Hirsh V, Thongprasert S, Tsai CM, Tan EH, Ho JC, Chu da T, Zaatar A, Osorio Sanchez JA, Vu VV, Au JS, Inoue A, Lee SM, Gebski V, Yang JC. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst 2013;105:595-605. 63. Kuan FC, Kuo LT, Chen MC, Yang CT, Shi CS, Teng D, Lee KD. Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis. Br J Cancer 2015;113:1519-1528. 64. Chiu CH, Shih YN, Tsai CM, Liou JL, Chen YM, Pemg RP. Serum tumor markers as predictors for survival in advanced non-small cell lung cancer patients treated with gefitinib. Lung Cancer 2007;57:213-221. 65. Saba R, Halytskyy O, Saleem N, Oliff IA. Buccal Epithelium, Cigarette Smoking, and Lung Cancer: Review of the Literature. Oncology 2017;93:347-353. 66. Singal G, Miller PG, Agarwala V, Li G, Kaushik G, Backenroth D, Gossai A, Frampton GM, Torres AZ, Lehnert EM, Bourque D, O’Connell C, Bowser B, Caron T, Baydur E, Seidl-Rathkopf K, Ivanov I, Alpha-Cobb G, Guria A, He J, Frank S, Nunnally AC, Bailey M, Jaskiw A, Feuchtbaum D, Nussbaum N, Abernethy AP, Miller VA. Association of Patient Characteristics and Tumor Genomics with Clinical Outcomes Among Patients with Non-Small Cell Lung Cancer Using a Clinicogenomic Database. JAMA 2019;321:1391-1399. 67. Stieber P, Holdenrieder S. Lung cancer biomarkers – Where we are and what we need. Cancer Biomark 2010;6:221-224. 68. Dube DH, Bertozzi CR. Glycans in cancer and inflammation--potential for therapeutics and diagnostics. Nat Rev Drug Discov 2005;4:477-488. 69. Yen HY, Liu YC, Chen NY, Tsai CF, Wang YT, Chen YJ, Hsu TL, Yang PC, Wong CH. Effect of sialylation on EGFR phosphorylation and resistance to tyrosine kinase inhibition. Proc Natl Sci USA 2015;112:6955-6960. 70. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008;358:1160-1174. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/73236 | - |
| dc.description.abstract | Pneumonia may progress to parapneumonic empyema. Streptococcus pneumoniae is the common pathogen. IL-17 produced by Th17 cells has a role to against Streptococcus pneumonia. However, old age and heart failure with reduced left ventricular ejection fraction are high risks for operation. This kind of patients developing parapneumonic empyema remain challenges for surgeons. To overcome this problem, a novel therapeutic protocol using non-intubated video assisted thoracoscopic surgery was applied. We investigated the morbidities, mortality, and quality of life in high risk parapneumonic empyema patients. There were two methods, conventional tube thoracostomy and non-intubated video assisted thoracoscopic surgery, to deal with the patients. The novel therapy surgery was proven to have better results of morbidities, mortality, and quality of life than conventional tube thoracostomy.
IL-17 of Th 17 response not only involves pulmonary inflammation, but promotes non-small cell lung cancer development. Epidermal growth factor receptor tyrosine kinase inhibitor therapy is the main treatment in advanced stage lung cancer patients harbored EGFR mutation. We retrospectively investigated the clinical characteristics and treatment outcomes of advanced stage lung cancer patients treated with tyrosine kinase inhibitor therapy. Non-smokers have a benefit in overall survival. Unfortunately, there are no good biomarkers to predict overall survival in advanced stage lung cancer. We detected sialylated LewisA, a cancer related O-glycan or CA 19-9, on lung cancer tumor cells. Immunohistochemistry staining was performed using sialylated LewisA antibody. There were sixty-six advanced stage patients receiving tyrosine kinase inhibitor therapy in our study. Positive immunohistochemistry staining patients (n=37) had better overall survival than negative immunohistochemistry staining patients (median survival time: 29.9 versus 12.5 months; p = 0.006). In proper selected lung cancer patients, sialylated LewisA or CA 19-9 immunohistochemistry staining may serve as a biomarker to predict overall survival. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-17T07:23:56Z (GMT). No. of bitstreams: 1 ntu-108-F00b48006-1.pdf: 2640647 bytes, checksum: 6435a9ad51a950df0cc7980b4e0dea01 (MD5) Previous issue date: 2019 | en |
| dc.description.tableofcontents | List of Abbreviations…………………………………………………………………...3
中文摘要…………………………………………………………………………….…5 Abstract…………………………………………………………………………………7 Part I. A Novel Protocol of Therapeutic Surgery in the Pulmonary Disease Chapter 1. Introduction…………………………………………………………………9 Chapter 2. Materials and Methods……………………………………………………..10 Chapter 3. Results……………………………………………………………………...13 Chapter 4. Discussion………………………………………………………………….15 Part II. Complicated Role of Interleukin-17 in the Pulmonary Diseases Chapter 5. Introduction………………………………………………………………...18 Chapter 6. Materials and Methods……………………………………………………..22 Chapter 7. Results……………………………………………………………………...25 Chapter 8. Discussion………………………………………………………………….28 References……………………………………………………………………………..32 Figures and Figure Legends………………………………………………………….44 Tables…………………………………………………………………………………..51 | |
| dc.language.iso | en | |
| dc.subject | 肺部疾病 | zh_TW |
| dc.subject | 癌抗原19-9 | zh_TW |
| dc.subject | pulmonary disease | en |
| dc.subject | CA 19-9 | en |
| dc.title | 評估治療性胸腔手術與白細胞介素17相關之肺部疾病 | zh_TW |
| dc.title | Assessment of a Novel Protocol of Therapeutic Surgery and the Complicated Role of Interleukin-17 in the Pulmonary Diseases | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 107-2 | |
| dc.description.degree | 博士 | |
| dc.contributor.oralexamcommittee | 陳晉興(Jin-Shing Chen),蔡勝國(Shen-Kou Tsai),莊依萍(Yi-Ping Chuang),陳威廷(Wei-Teing Chen) | |
| dc.subject.keyword | 肺部疾病,癌抗原19-9, | zh_TW |
| dc.subject.keyword | pulmonary disease,CA 19-9, | en |
| dc.relation.page | 53 | |
| dc.identifier.doi | 10.6342/NTU201901127 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2019-07-02 | |
| dc.contributor.author-college | 生命科學院 | zh_TW |
| dc.contributor.author-dept | 基因體與系統生物學學位學程 | zh_TW |
| 顯示於系所單位： | 基因體與系統生物學學位學程 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-108-1.pdf 未授權公開取用 | 2.58 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。